-
1
Early mortality after chemotherapy serves as a quality indicator in cancer care, reflecting treatment toxicity and healthcare delivery effectiveness.
-
2
In leukemia, 4-week mortality post-induction chemotherapy varies significantly between academic and non-academic centers, indicating differing care levels.
-
3
Therapies administered close to death may reflect poor care decisions, but withholding treatment can negatively impact quality of life and survival.
-
4
Novel therapies in leukemia can yield significant benefits even in terminal patients, challenging the notion of withholding treatment at end-of-life.
-
5
Latent variables significantly affect early mortality comparisons, complicating the assessment of quality care across different healthcare settings.
